SECURITIES | 2026-11-18
Caremark Duties: When Directors Can Be Held Liable for Failing to Oversee the Company
How the duty of oversight works, why Caremark claims were once called the hardest in corporate law, and how Marchand v. Barnhill and the Boeing decision revived director liability for boards that ignore mission-critical risk
By Anatolii Trembach, Esq. (California State Bar No. 349304; LL.M., USC Gould School of Law; admitted to the U.S. Court of International Trade), Trembach Law Firm, APC · Published
Corporate directors owe their company and its shareholders fiduciary duties of care and loyalty, but one branch of those duties has drawn intense attention from investors, regulators, and the courts: the duty of oversight. Under the doctrine that takes its name from a 1996 Delaware decision,...
The Fiduciary Duties of Corporate Directors
Directors of a corporation stand in a fiduciary relationship to the company and its shareholders. That relationship imposes duties traditionally described as the duty of care — to act on an informed basis and with the attention a reasonably prudent person would use — and the duty of loyalty — to act in the best interests of the corporation rather than for personal gain. Delaware, whose corporate law governs a large share of public companies and influences courts nationwide, has long recognized these duties, and California imposes comparable obligations on directors under California Corporations Code § 309, which requires a director to perform his or her duties in good faith, in a manner the director believes to be in the best interests of the corporation and its shareholders, and with the care an ordinarily prudent person would use. Within this framework, the duty of oversight occupies a special place: it addresses not a decision the board made badly, but the board's failure to put itself in a position to know what the company was doing at all.
The Origin: In re Caremark
The oversight duty is named for In re Caremark International Inc. Derivative Litigation, 698 A.2d 959 (Del. Ch. 1996). In approving a settlement of a derivative suit arising from a healthcare company's criminal and civil liability, Chancellor Allen articulated the principle that a board's obligation includes a duty to attempt in good faith to assure that a corporate information and reporting system exists, and that the failure to do so, under some circumstances, could render a director liable for losses caused by non-compliance with applicable legal standards. Caremark reframed director liability for a failure to monitor as a question of good faith: directors do not guarantee good outcomes, but they must make a genuine, good-faith effort to establish the systems that let the board oversee the enterprise. The decision recognized that in a large corporation the board cannot know everything, but it must at least ensure that mechanisms are in place to bring important compliance and risk information to its attention.
Stone v. Ritter and the Good-Faith Standard
The Delaware Supreme Court adopted and refined the Caremark standard in Stone v. Ritter, 911 A.2d 362 (Del. 2006). Stone held that the duty of oversight is a component of the duty of loyalty, grounded in the obligation to act in good faith, and it set out two ways a director can breach it. Oversight liability arises where "(a) the directors utterly failed to implement any reporting or information system or controls; or (b) having implemented such a system or controls, consciously failed to monitor or oversee its operations thus disabling themselves from being informed of risks or problems requiring their attention." Critically, Stone held that in either case, "imposition of liability requires a showing that the directors knew that they were not discharging their fiduciary obligations." That scienter requirement — a showing of conscious disregard, not mere negligence — is what made Caremark claims so hard to win. A plaintiff cannot prevail simply by showing that the board's monitoring was imperfect or that a disaster occurred; the plaintiff must show that the directors consciously failed to act, knowing they were abandoning their responsibilities. Because scienter is difficult to plead with particularity, oversight claims were long regarded as nearly impossible to sustain.
The Business Judgment Rule and Director Protection
The difficulty of oversight claims is reinforced by two protective doctrines. The business judgment rule presumes that in making a business decision, directors acted on an informed basis, in good faith, and in the honest belief that the action was in the corporation's best interests; a plaintiff must rebut that presumption to subject the decision to closer scrutiny. In addition, many corporations adopt charter provisions authorized by 8 Del. C. § 102(b)(7) (and California companies may limit director liability within statutory bounds) that exculpate directors from monetary liability for breaches of the duty of care — but not for breaches of the duty of loyalty or for acts not in good faith. Because the oversight duty sounds in loyalty and good faith, exculpation provisions do not shield directors from a well-pleaded Caremark claim. This is why the oversight theory, although hard to plead, is potent when it succeeds: it reaches conduct that the usual protections do not cover, exposing directors to personal liability that an exculpation clause cannot erase.
Marchand v. Barnhill: The Revival
For more than two decades after Caremark, few oversight claims survived a motion to dismiss. That pattern broke in Marchand v. Barnhill, 212 A.3d 805 (Del. 2019), the Blue Bell ice cream listeria case. A listeria outbreak in the company's products led to deaths and a recall, and shareholders sued, alleging the board had failed to oversee food safety. The Delaware Supreme Court reversed the dismissal, holding that the complaint stated a Caremark claim. The Court emphasized that food safety was the company's mission-critical and essential operation — for a food company, a safe product is the central compliance concern — and that the board had failed to make a good-faith effort to put in place a board-level system to monitor that critical risk. The Court faulted the board for having no committee charged with food-safety oversight, no protocol requiring management to report food-safety issues to the board, and no regular board discussion of the topic, even as regulators flagged problems. Marchand reframed the first prong of Stone: when a risk is mission-critical, the board must ensure that a board-level reporting system for that risk exists, and a board that leaves such a central risk entirely to management without any monitoring mechanism of its own may face liability.
The Boeing Decision and Mission-Critical Risk
The oversight doctrine gained further force in In re The Boeing Co. Derivative Litigation, 2021 WL 4059934 (Del. Ch. 2021), arising from the two fatal 737 MAX crashes. The Court of Chancery held that shareholders had stated a Caremark claim against Boeing's directors, finding that airplane safety was mission-critical for an aircraft manufacturer and that the board had failed to establish a committee or reporting system dedicated to monitoring product and passenger safety, and had not meaningfully responded to the first crash before the second occurred. Boeing confirmed the trajectory Marchand began: where a company's central risk is one whose failure threatens lives or the enterprise itself, directors must affirmatively ensure that information about that risk reaches the board, and they must act when red flags appear. The combination of Marchand and Boeing signaled to boards across industries that oversight of mission-critical risk is not a passive obligation that can be delegated entirely to management, but an active, board-level duty whose neglect can lead to personal liability that exculpation clauses do not reach.
What Boards Must Now Do
The revived oversight doctrine has practical implications for how boards operate. To meet the duty as the recent cases describe it, a board should identify the company's mission-critical risks — the compliance and safety concerns central to its business and survival; establish a board-level monitoring system for those risks, typically including a dedicated committee or a clear reporting protocol requiring management to bring critical-risk information to the board; document the board's attention to those risks in minutes and materials; and, when red flags arise, respond rather than defer. The lesson of Marchand and Boeing is not that boards must guarantee against every failure, but that they must build and use the machinery of oversight for the risks that matter most. A board that can show it created a genuine, functioning board-level system for monitoring its mission-critical risks, and that it engaged with the information that system produced, stands on far firmer ground than a board that left such risks entirely to management and learned of the problem only when it became a crisis.
Oversight Claims and Shareholder Derivative Litigation
Oversight claims typically arise as shareholder derivative actions — suits brought by shareholders on behalf of the corporation to recover for harm the directors allegedly caused the company. Derivative suits carry their own procedural demands, including the requirement that the shareholder either make a demand on the board to pursue the claim or plead with particularity why demand would be futile. The scienter element of a Caremark claim interacts with these requirements, because a plaintiff must plead particularized facts — often obtained through books-and-records inspection — showing that the directors consciously failed in their oversight role. The recent cases underscore the value of a books-and-records investigation before filing, so that the derivative complaint can allege, with specificity, the absence of a board-level monitoring system or the board's conscious disregard of red flags. For shareholders, the revival of Caremark means a viable, if still demanding, theory for holding directors accountable; for directors, it means that governance records increasingly matter, because those records will be scrutinized if an oversight claim is brought.
Federal Securities Overlap
A failure of oversight that leads to a corporate crisis frequently travels with federal securities exposure. When a company's disclosures about its risk management, safety, or compliance prove false or misleading, shareholders may assert claims under the federal securities laws, including Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 (17 C.F.R. § 240.10b-5), and the proxy rules under Section 14(a) (15 U.S.C. § 78n(a)). Books-and-records provisions under Section 13(b)(2) of the Exchange Act also require issuers to maintain accurate records and adequate internal accounting controls, a federal analog to the state-law monitoring concern. While the Caremark duty is a matter of state corporate fiduciary law and the securities claims arise under federal statute, the same underlying failure — a board that did not monitor a critical risk and a company that misrepresented its controls — can generate parallel litigation on both tracks. Advisors therefore analyze a governance failure for both its state fiduciary and its federal disclosure dimensions.
Why This Matters for California Companies and Investors
Although the leading oversight cases are decided under Delaware law, their influence extends to California companies, many of which are incorporated in Delaware, and California's own director-duty standard under Corporations Code § 309 echoes the good-faith and prudent-oversight themes. For directors of California technology, life-sciences, and manufacturing companies — many of which operate businesses with their own mission-critical safety, data, or compliance risks — the revived oversight doctrine is a clear signal to build and use board-level monitoring systems. For investors, it is a renewed avenue of accountability. The thread connecting Caremark, Stone, Marchand, and Boeing is that directors cannot be passive; good faith requires that the board put itself in a position to know, and then act on, the risks most central to the enterprise. For more on the firm's work in this area, see our securities and corporate governance practice and our mergers and acquisitions practice.
The Extension of Oversight Duties to Officers
For most of its history, the Caremark doctrine was understood as a duty of directors. The Delaware Court of Chancery has since made clear that corporate officers owe an analogous oversight duty. In In re McDonald's Corporation Stockholder Derivative Litigation, 289 A.3d 343 (Del. Ch. 2023), the court held that officers, like directors, owe a duty of oversight as a component of the duty of loyalty, and that an officer can be liable for consciously disregarding red flags within the officer's area of responsibility. The court reasoned that officers are often closer to the company's day-to-day operations than directors and are frequently the source of the information that reaches the board, so it would make little sense to impose an oversight obligation on directors but not on the officers who run the relevant functions. The officer's oversight duty is generally confined to the officer's own sphere of authority — a chief financial officer's oversight obligations center on financial reporting and controls, for example — whereas the board's duty spans the enterprise. The recognition of an officer-level oversight duty expands the universe of potential defendants in a derivative suit and reinforces the broader message of the modern cases: those responsible for monitoring a company's critical risks, whether in the boardroom or the executive suite, cannot consciously ignore the warning signs their position requires them to heed. For a California company, this development underscores that compliance-monitoring responsibilities, and the accompanying exposure, run through the management ranks and not only the board.
- Securities & Corporate Governance News
- Revlon Duties: A Board's Obligation to Maximize Value in a Sale of Control
- SPACs and De-SPAC Mergers: Shareholder Redemption Rights, Fiduciary Duties, and Disclosure Liability
- Proxy Fraud Under Section 14(a) and Rule 14a-9 in California: When a False or Misleading Proxy Statement Gives Shareholders a Claim, What Materiality Requires, and How Causation Is Proven
Frequently Asked Questions
What is a Caremark claim?
A Caremark claim alleges that corporate directors breached their fiduciary duty of oversight — either by utterly failing to implement any reporting or information system, or by consciously failing to monitor a system they did implement. It takes its name from In re Caremark, 698 A.2d 959 (Del. Ch. 1996).
What is the legal standard for oversight liability?
Under Stone v. Ritter, 911 A.2d 362 (Del. 2006), the duty of oversight is part of the duty of loyalty and requires good faith. Liability requires a showing that the directors knew they were not discharging their fiduciary obligations — a scienter (conscious-disregard) standard, not mere negligence.
Why were Caremark claims considered so hard to win?
Because the plaintiff must plead particularized facts showing the directors consciously disregarded their oversight duties. Imperfect monitoring or a bad outcome is not enough; the plaintiff must show a knowing failure, which is difficult to establish.
How did Marchand v. Barnhill change things?
Marchand, 212 A.3d 805 (Del. 2019), revived oversight liability by holding that when a risk is mission-critical — food safety for a food company — the board must ensure a board-level reporting system exists for that risk. A board that leaves a central risk entirely to management may face liability.
What was the Boeing decision about?
In re Boeing, 2021 WL 4059934 (Del. Ch. 2021), arose from the 737 MAX crashes and sustained a Caremark claim, finding airplane safety mission-critical and faulting the board for having no dedicated safety-monitoring system and for not responding adequately to the first crash before the second.
Do exculpation clauses protect directors from Caremark claims?
No. Charter provisions under 8 Del. C. § 102(b)(7) exculpate directors from monetary liability for duty-of-care breaches but not for breaches of loyalty or acts not in good faith. Because oversight sounds in loyalty and good faith, exculpation does not shield a well-pleaded Caremark claim.
What should a board do to meet its oversight duty?
Identify the company's mission-critical risks, establish a board-level monitoring system (committee or reporting protocol) for them, document the board's attention in minutes and materials, and respond to red flags rather than defer to management.
How are oversight claims brought?
Usually as shareholder derivative suits on the company's behalf, subject to demand or demand-futility requirements. Plaintiffs often use a books-and-records inspection first to gather particularized facts about the board's monitoring systems and response to red flags.
Speak With a California Securities and Governance Attorney
If you are a director concerned about oversight exposure, a board building a compliance-monitoring system, or a shareholder evaluating a derivative claim for a failure of oversight, Trembach Law Firm can help. We advise on fiduciary duties, board monitoring of mission-critical risk, and governance litigation. For a consultation, call (818) 514-7680. The revival of the Caremark doctrine has made board-level oversight of critical risk a matter of real personal consequence for directors — and a renewed avenue of accountability for investors.
This article is provided for general informational purposes only and is not legal advice. Reading it does not create an attorney-client relationship. Every matter depends on its own facts, and no particular outcome is guaranteed.
Contact Trembach Law Firm at (818) 514-7680 for a confidential consultation.
Trembach Law Firm | 27001 Agoura Road, Suite 350, Calabasas, CA 91301